Dabigatran PCD Pharma Franchise Company

Cafoli Lifecare offers a Dabigatran range of 3 capsule formulations, manufactured in WHO-GMP certified facilities. Distributors serving cardiology, neurology and orthopaedic prescribers can secure district-wise monopoly franchise rights for this modern oral anticoagulant with full promotional support.

What is Dabigatran?

Dabigatran etexilate is a direct oral anticoagulant (DOAC) that directly and reversibly inhibits thrombin. It prevents clot formation with predictable dosing and without routine INR monitoring, offering a convenient alternative to warfarin. Reference: PubChem - Dabigatran etexilate.

Available Forms

The Cafoli Dabigatran portfolio is offered as oral Capsules in the standard strengths (75mg, 110mg, 150mg). Contact us for current pack presentations and trade offers.

Therapeutic Applications

Dabigatran is prescribed to prevent stroke and systemic embolism in non-valvular atrial fibrillation, to treat and prevent deep-vein thrombosis and pulmonary embolism, and for thromboprophylaxis after major orthopaedic surgery. Prescribers include cardiologists, neurologists, physicians and orthopaedic surgeons.

Why Dabigatran is a High-Potential Molecule for Distributors

Direct oral anticoagulants are rapidly replacing warfarin because they need no routine blood monitoring, and use is climbing with rising atrial fibrillation and an ageing population. As a lifelong therapy prescribed by specialists, dabigatran delivers high-value, predictable monthly refills and positions a distributor in the fast-growing modern-cardiology segment.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.

References

1. PubChem: Dabigatran etexilate
2. MedlinePlus: Dabigatran
3. PubMed: dabigatran in atrial fibrillation